These results perfectly correlated with those obtained in in vitro studies after treating sensitive NSCLC cell lines with progressively increasing doses of gefitinib or other EGFR inhibitors [57,58,70,90,91]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.